| |
 |
This program was derived from a live symposium that took place at the 2000 American Medical Directors Association Meeting. The live symposium was CME accredited. This web-based program is not continuing education accredited.
Needs Assessment
More frequently than not, major depression is accompanied by underlying anxiety, which is often recognized and, therefore, untreated. Unless the presence of both disorders is considered when treatment is begun, this comorbidity can result in patients refractory to antidepressant therapy alone. Optimal treatment also requires assessment of pharmacotherapeutics' potential for drug interactions.
Learning Objectives
Following completion of the symposium attendees should be able to:
- Cite the frequent comorbidity of depression and anxiety.
- Discuss the importance of treating both disorders.
- State the value of treating beyond better, to well.
- Describe the considerations necessary in choosing pharmacotherapy.
- Identify the role of the medical director in ensuring optimal treatment.
Supported through an unrestricted educational grant from 
|
